Top Markets
#1 ONFA ONFA +218.69%
#2 Resolv wstUSR Resolv wstUSR +198.08%
#3 NKN NKN +48.56%
#4 Noon Noon +41.33%
#5 Doge Strategy Doge Strategy +38.28%
#6 DeAgentAI DeAgentAI +30.80%
#7 StakeStone StakeStone +29.13%
#8 BLOCKv BLOCKv +28.38%
#9 OpenVPP OpenVPP +21.65%
#10 TronBank TronBank +16.89%
Coin of the day
ONFA ONFA
Settings
Language
ENGLISH
Currency
USD
Theme
Ensysce Biosciences, Inc. Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSC
Rank in Stocks #19705
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in... Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Share Price
$0.5275
Market Cap
$1.25M
Change (1 day)
-3.56%
Change (1 year)
-83.77%
Country
US
Trade Ensysce Biosciences, Inc. (ENSC)

Category

Healthcare
P/E ratio for Ensysce Biosciences, Inc. (ENSC)
P/E ratio as of March 2026 TTM: -0.11
According to Ensysce Biosciences, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.11. At the end of 2023 the company had a P/E ratio of -3.39.
P/E ratio history for Ensysce Biosciences, Inc. from 2017 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) -0.11 -93.99%
2024 -1.78 -47.51%
2023 -3.39 237.53%
2022 -1.00 -97.94%
2021 -48.88 -100.00%
2020 3.52M 463.02%
2019 624.36K -494.92%
2018 -158.10K -97.60%
2017 -6.60M 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 10.72 -10,115.98%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 30.14 -28,271.96%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 17.03 -16,020.28%
US
UCB SA UCB SA
UCB SA
UCB.BR
 30.44 -28,547.20%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 33.07 -31,009.72%
AU
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.